Holen Sie sich die Stockscreener-App
111.93
2.25%
-2.62
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$114.55
Offen:
$113.67
24-Stunden-Volumen:
1.83M
Relative Volume:
0.28
Marktkapitalisierung:
$138.82B
Einnahmen:
$28.80B
Nettoeinkommen (Verlust:
$6.31B
KGV:
22.30
EPS:
5.02
Netto-Cashflow:
$9.37B
1W Leistung:
-3.37%
1M Leistung:
-5.41%
6M Leistung:
+0.48%
1J Leistung:
+35.21%
1-Tages-Spanne:
$111.33
$113.67
1-Wochen-Bereich:
$111.33
$118.11
52-Wochen-Spanne:
$81.83
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
111.88 | 142.13B | 28.80B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
750.04 | 677.17B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.83 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
215.55 | 385.71B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.50 | 240.28B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
81.70 | 206.84B | 63.43B | 16.42B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences, Inc. $GILD Shares Sold by Pensionfund Sabic - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Focus Partners Wealth - MarketBeat
Ilmarinen Mutual Pension Insurance Co Acquires 21,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Raised by Fred Alger Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Glenview Trust co - MarketBeat
Ascent Group LLC Buys 11,200 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Meiji Yasuda Life Insurance Co Buys 2,945 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
AG2R LA Mondiale Gestion D Actifs Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Voya Investment Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Swedbank AB - MarketBeat
Kestra Investment Management LLC Sells 2,391 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Voleon Capital Management LP Sells 34,020 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CTC Alternative Strategies Ltd. Invests $784,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Strs Ohio Buys Shares of 512,180 Gilead Sciences, Inc. $GILD - MarketBeat
Jacobi Capital Management LLC Has $2.59 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Geneos Wealth Management Inc. Sells 10,330 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Acadian Asset Management LLC Buys 189,569 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
WBI Investments LLC Sells 7,266 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
SCS Capital Management LLC Invests $853,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock - Yahoo Finance
Gilead beats whistleblower lawsuit over hepatitis C drugs - Reuters
UniSuper Management Pty Ltd Acquires 137,308 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead prevails in whistleblower lawsuit over alleged hepatitis C prescription kickbacks - Fierce Pharma
Intech Investment Management LLC Sells 54,585 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Position Increased by IFM Investors Pty Ltd - MarketBeat
Gilead Defeats Whistleblower’s Hepatitis C Kickback Suit (1) - Bloomberg Law News
Rothschild & Co Redburn Adjusts Gilead Sciences Price Target to $143 From $136, Maintains Buy Rating - MarketScreener
Gilead Sciences, Inc. : The underlying trend is in force again - MarketScreener
Gilead Sciences stock price target raised to $143 from $136 at Rothschild Redburn - Investing.com
State of Wyoming Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite - simplywall.st
Ex-Dividend Reminder: Gilead Sciences, Thermo Fisher Scientific and Merck - Nasdaq
Sanofi wins big at the 2025 Fierce Pharma Marketing Awards - Fierce Pharma
Zurich Insurance Group Ltd FI Cuts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Cinctive Capital Management LP Cuts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Continental Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Gotham Asset Management LLC - MarketBeat
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? - Stocktwits
Parkman Healthcare Partners LLC Cuts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead, Moderna to see upside if RFK Jr. leaves HHS: RBC - MSN
Gilead at Baird Global Healthcare Conference: Expanding Cell Therapy Horizons - Investing.com
Gilead Sciences Commits to Veeva Vault CRM - Contract Pharma
Curi RMB Capital LLC Has $8.92 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Commits to Veeva Vault Crm - MarketScreener
Should Income Investors Look At Gilead Sciences, Inc. (NASDAQ:GILD) Before Its Ex-Dividend? - 富途牛牛
Veeva Systems says Gilead Sciences commits to Veeva Vault CRM - MarketScreener
Gilead Sciences commits to Veeva Vault CRM - Investing.com
Veeva Systems Expands Partnership With Gilead Sciences - MarketScreener
Veeva Systems partners with Gilead for Vault CRM (VEEV:NYSE) - Seeking Alpha
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):